V.P. Stus - Concepedia

Author

V.P. Stus

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

Eduard Stakhovsky, V Stus, V. P. Stus, V. P. Stus', V. Stus, V. Stus', V.P. Stus, Viktor P Stus, Viktor P. Stus, Viktor Stus

Publications

6.6K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Université Laval University College London Fox Chase Cancer Center Central Clinical Hospital and Polyclinic

About

V.P. Stus is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in urology, medicine, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	15	1.9K
2	Pharmacology	7	7	343
3	Health Sciences	6	6	360
4	Immunology	2	2	130
5	Pathology	1	1	12

V.P. Stus

Publications

6.2K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma Brian I. Rini, Elizabeth R. Plimack, V.P. Stus, New England Journal of Medicine	2019	3.3K
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial Thomas Powles, Elizabeth R. Plimack, Denis Soulières, The Lancet Oncology UrologyOncologyGenitourinary CancerImmune Checkpoint InhibitorFirst-line Treatment	2020	721
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial Thomas E. Hutson, Vladimir Lesovoy, V.P. Stus, The Lancet Oncology First-line TherapyUrologyAxitinib Versus SorafenibMetastatic Renal-cell CarcinomaGenitourinary Cancer	2013	404
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections J. Motsch, Cláudia Murta de Oliveira, V.P. Stus, Clinical Infectious Diseases	2019	384
Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection Keith S. Kaye, Tanaya Bhowmick, Symeon Metallidis, JAMA	2018	298
Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial Keith S. Kaye, Louis B. Rice, Aaron Dane, Clinical Infectious Diseases	2019	135
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial Laurence Albigès, Howard Gurney, Vagif Atduev, The Lancet Oncology First-line TherapyUrologyGenitourinary CancerMedicineImmune Checkpoint Inhibitor	2023	130
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. Brian I. Rini, Elizabeth R. Plimack, V.P. Stus, Journal of Clinical Oncology ImmunologyImdc Intermediate/poor RiskPharmacotherapyKeynote-426 StudyImdc Risk Groups	2019	118
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial Hiddo J.L. Heerspink, C. David Sjöström, Niels Jongs, European Heart Journal	2021	118
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study Elizabeth R. Plimack, Thomas Powles, V.P. Stus, European Urology UrologyGenitourinary CancerMedicineImmune Checkpoint InhibitorFirst-line Treatment	2023	118

Page 1